Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Eli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too ...

Eli Lilly’s experimental weight-loss drug retatrutide led to an average weight reduction of up to 28.7%—more than 71 ...

Eli Lilly (LLY) stock gains as the company's next-generation weight loss candidate, retatrutide succeeds in a Phase 3 trial.

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient ...

Eli Lilly and Company (NYSE: LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on ...